Goldman Sachs Group Inc Cytokinetics Inc Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,362,958 shares of CYTK stock, worth $41.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,362,958
Previous 1,382,558
1.42%
Holding current value
$41.3 Million
Previous $55.6 Million
1.42%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$444 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$359 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$301 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$242 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$184 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.85B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...